Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07921654). This is a study registration, not published results. Lead sponsor: Capital Medical University. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 156 participants (ESTIMATED). Conditions: Major Depressive Disorder (MDD). Interventions: OTHER: Acute Intermittent Hypoxia (AIH); OTHER: Normoxic Sham Intervention; DEVICE: Acute Intermittent Hypoxia Delivery Device; DEVICE: Acute Intermittent Hypoxia Delivery Device. Primary outcome measures: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 2 (After 10 Treatment Sessions) , Baseline to the end of 10 treatment sessions (Week 2).. Brief summary: The goal of this clinical trial is to evaluate the efficacy of acute intermittent hypoxia for the treatment of patients with major depressive disorder. The study will also assess the safety and tolerability of acute intermittent hypoxia and explore its potential mechanisms underlying its antidepressant effects.